Julie E Seas, PHARMACIST in Arlington, SD - Pharmacist

Julie E Seas, PHARMACIST is a Pharmacist based in Arlington, South Dakota. Julie E Seas is licensed to practice in South Dakota (license number 3905) and her current practice location is 125 So Main St, Arlington, South Dakota. She can be reached at her office (for appointments etc.) via phone at (605) 983-5711.

NPI number for Julie E Seas is 1740381631 and her current mailing address is 504 W Hickory St, Arlington, South Dakota. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1740381631.

Contact Information

	Julie E Seas, PHARMACIST
	125 So Main St, Arlington, SD 57212-0384
	(605) 983-5711
	(605) 983-5711

Healthcare Provider's Profile

Full Name	Julie E Seas
Gender	Female
Speciality	Pharmacist
Location	125 So Main St, Arlington, South Dakota
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1740381631
Provider Enumeration Date: 09/26/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Julie E Seas such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1740381631	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	3905 (South Dakota)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Julie E Seas is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Julie E Seas, PHARMACIST 504 W Hickory St, Arlington, SD 57212 Ph: (605) 983-5538	Julie E Seas, PHARMACIST 125 So Main St, Arlington, SD 57212-0384 Ph: (605) 983-5711

News Archive

Scientists use two methods to manipulate disease-causing mutations in stem cells

Using two distinct methods, Whitehead Institute researchers have successfully and consistently manipulated targeted genes in both human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells.

New Hora de Hablar CARDIO program launched to help better manage heart health

An innovative new program, Hora de Hablar CARDIO – Creando la Atencion Real y Dialogo Inmediato en la Oficina, launched today to encourage patients and health care professionals to actively partner to help better manage heart health through more productive conversations during medical visits.

Research identifies new therapeutic target for cancer treatment and tissue regeneration

Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration - a protein called Prominin-1.

Research explains why those with obstructive sleep apnea are at higher risk for cardiovascular disease

Researchers have found that patients with obstructive sleep apnea (OSA) have higher levels of a type of dead cells (apoptotic cells) from the lining (endothelium) of their blood vessels circulating in their bloodstream than people who do not have OSA.

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation.

Julie E Seas, PHARMACIST - Pharmacist in Arlington, SD